Alkermes (ALKS) Long-Term Debt Issuances (2013 - 2026)
Alkermes (ALKS) posted quarterly Long-Term Debt Issuances of $1.5 billion for Q1 2026, up 6313.87% quarter-over-quarter from $23.6 million in Q1 2021.
Alkermes (ALKS) Long-Term Debt Issuances (2013 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Long-Term Debt Issuances for 3 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $1.5 billion (changed N/A YoY), while the FY2021 annual figure was $23.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances advanced to $1.5 billion in Q1 2026 per ALKS's latest filing, from $23.6 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $1.5 billion in Q1 2026 and bottomed at $1.5 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Bn |
| Mar 31, 2026 | 1.51 Bn |
| Mar 31, 2021 | 23.57 Mn |
| Mar 31, 2021 | 23.57 Mn |
| Mar 31, 2013 | -2.07 Mn |
| Mar 31, 2013 | -2.07 Mn |